journal article·2022-11-16

Leveraging Nanodrug Delivery System for Simultaneously Targeting Tumor Cells and M2 Tumor-Associated Macrophages for Efficient Colon Cancer Therapy

Jun Zeng, Yanju Sun, Shuo Sun, Mingxia Jiang, Daijuan Zhang, Wentong Li, Zhijun Liu, Hongcai Shang, Xiuwen Guan, Weifen Zhang

ACS Applied Materials & Interfaces· Volume 14· Issue 45
Publisher page

Abstract

Tumor-associated macrophages (TAMs) widely exist in the solid tumors, which participate in the entire course of tumor development and execute momentous impacts. Therefore, manipulating TAMs has been identified as an expecting strategy with immense potential for cancer therapy. Herein, a nanodrug delivery system was leveraged for simultaneously targeting tumor cells and M2-type TAMs for efficient colon cancer therapy. The broad-spectrum anticancer chemotherapeutic drug doxorubicin (DOX) was hitchhiked in a mannose-modified bovine serum albumin (MAN-BSA) carrier. The DOX@MAN-BSA nanodrug delivery system was verified to possess feasible physical performances for unhindered systemic circulation and active targeting on colon tumors. DOX@MAN-BSA nanoparticles could be preferentially swallowed by colon tumor cells and M2 TAMs through mannose receptor-mediated endocytosis. Further in vivo antitumor therapy in CT26 colon tumor-bearing mice has achieved remarkable suppression efficacy with satisfactory biosafety. Leveraging the nanodrug delivery system for simultaneously targeting tumor cells and M2 TAMs has contributed a feasible strategy to collaboratively repress the malignant tumor cells and the collusive M2 TAMs for efficient cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immune cells in cancer · Nanoplatforms for cancer theranostics · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Pharmacy, Weifang Medical University, Weifang 261053, China

Department of Pathology, Weifang Medical University, Weifang 261053, China

Department of Medical Microbiology, Weifang Medical University, Weifang 261053, China

Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shandong Province

References (49)

Show source-provided references
1. 10.1016/j.smim.2017.09.00410.1016/j.smim.2017.09.004 ↗
2. 10.3389/fimmu.2020.0173110.3389/fimmu.2020.01731 ↗
3. 10.1016/j.bcp.2020.11435410.1016/j.bcp.2020.114354 ↗
4. 10.1186/s12929-019-0568-z10.1186/s12929-019-0568-z ↗
5. 10.1016/j.it.2019.02.00310.1016/j.it.2019.02.003 ↗
6. 10.1038/s41392-021-00484-910.1038/s41392-021-00484-9 ↗
7. 10.1016/j.jconrel.2021.11.02810.1016/j.jconrel.2021.11.028 ↗
8. 10.1021/acsabm.1c0046110.1021/acsabm.1c00461 ↗
9. 10.3389/fonc.2019.0151210.3389/fonc.2019.01512 ↗
10. 10.1165/rcmb.2015-0012OC10.1165/rcmb.2015-0012OC ↗
11. 10.30579/mbse.2019.2.1.110.30579/mbse.2019.2.1.1 ↗
12. 10.1002/jcp.2642910.1002/jcp.26429 ↗
13. 10.1016/j.apsb.2020.04.00410.1016/j.apsb.2020.04.004 ↗
14. Sica A. · Exp. Oncol. · 2010 · 32 · 153
15. 10.4161/cc.9.24.1432210.4161/cc.9.24.14322 ↗
16. 10.1080/10717544.2021.192107610.1080/10717544.2021.1921076 ↗
17. 10.1016/j.clim.2010.06.01710.1016/j.clim.2010.06.017 ↗
18. 10.3390/cancers603167010.3390/cancers6031670 ↗
19. 10.1186/s12935-021-02089-210.1186/s12935-021-02089-2 ↗
20. 10.1016/j.yexcr.2019.03.00510.1016/j.yexcr.2019.03.005 ↗
21. 10.3390/pharmaceutics1310167010.3390/pharmaceutics13101670 ↗
22. 10.1016/j.cellimm.2016.11.00210.1016/j.cellimm.2016.11.002 ↗
23. 10.1016/j.nantod.2022.10140010.1016/j.nantod.2022.101400 ↗
24. 10.1158/1078-0432.CCR-19-325910.1158/1078-0432.CCR-19-3259 ↗
25. Bense R. D. · JNCI, J. Natl. Cancer Inst. · 2017 · 109 · djw19210.1093/jnci/djw192 ↗
26. 10.1186/s13046-022-02272-x10.1186/s13046-022-02272-x ↗
27. 10.1002/adhm.20210059010.1002/adhm.202100590 ↗
28. 10.1158/0008-5472.CAN-14-339410.1158/0008-5472.CAN-14-3394 ↗
29. 10.1016/j.cej.2022.13477910.1016/j.cej.2022.134779 ↗
30. 10.1002/adtp.20190018110.1002/adtp.201900181 ↗
31. 10.1002/adma.20180830310.1002/adma.201808303 ↗
32. 10.1126/scitranslmed.aax633710.1126/scitranslmed.aax6337 ↗
33. 10.3390/ijms1805097910.3390/ijms18050979 ↗
34. Jahagirdar P. · 2019 · 43310.1007/978-3-030-29168-6_15 ↗
35. 10.1080/02652048.2017.133973910.1080/02652048.2017.1339739 ↗
36. 10.1016/B978-0-12-820757-4.00008-910.1016/B978-0-12-820757-4.00008-9 ↗
37. 10.1007/s10853-019-03486-910.1007/s10853-019-03486-9 ↗
38. 10.1016/j.lwt.2015.11.06110.1016/j.lwt.2015.11.061 ↗
39. 10.1002/adfm.20170040310.1002/adfm.201700403 ↗
40. 10.1039/C7SC04853J10.1039/C7SC04853J ↗
41. 10.1007/s10118-012-1156-910.1007/s10118-012-1156-9 ↗
42. 10.1039/c2jm16831f10.1039/c2jm16831f ↗
43. 10.18632/oncotarget.1862710.18632/oncotarget.18627 ↗
44. 10.1038/s41419-018-1285-310.1038/s41419-018-1285-3 ↗
45. 10.1002/adma.20200417210.1002/adma.202004172 ↗
46. 10.1021/acsami.7b1121910.1021/acsami.7b11219 ↗
47. 10.1039/D0NR08050K10.1039/D0NR08050K ↗
48. 10.7150/jca.4969210.7150/jca.49692 ↗
49. 10.1002/ijc.3340810.1002/ijc.33408 ↗